Pure Global AI
NCT06215755Recruiting

A Study of VRG50635 in Participants With Amyotrophic Lateral Sclerosis (ALS)

A Phase 1b, Open-Label, Multiple Ascending Dose, Multicenter Study of VRG50635 in Participants With Sporadic and Familial Amyotrophic Lateral Sclerosis Followed by Long-Term Treatment
Verge GenomicsPhase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Amyotrophic Lateral Sclerosis
Drug/Device/Intervention
VRG50635
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Verge Genomics
Location
Montreal,Utrecht, Canada,Netherlands
Timeline & enrollment
Phase
Phase 1
Start date
Jan 15, 2024
End date
Jun 01, 2026
Enrollment
50 participants
Primary outcome

Number of Participants with Treatment-emergent Adverse Events (TEAEs),Number of Participants with Clinical Laboratory Evaluation Abnormalities,Number of Participants with Vital Sign Abnormalities,Number of Participants with Electrocardiogram (ECG) Abnormalities,Number of Participants with Physical Examination Abnormalities,Number of Participants with Neurological Examination Abnormalities

Summary

The primary purpose of this study is to evaluate the safety and tolerability of VRG50635 in
 participants with ALS.

ICD-10 classifications
Neuralgic amyotrophyMotor neuron diseaseOther degenerative diseases of the nervous systemOther degenerative disorders of nervous system in diseases classified elsewhereMultiple sclerosis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06215755
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06215755 through Pure Global AI's free database. This Phase 1 trial is sponsored by Verge Genomics and is currently Recruiting. The study focuses on Amyotrophic Lateral Sclerosis. Target enrollment is 50 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.